Index

AAI. See Age-at-interview (AAI)
ADHD. See Attention-Deficit Hyperactivity Disorder (ADHD)
AG. See Agoraphobia (AG)
age at interview (AAI), 63
age-of-onset (AOO), 19, 21, 24, 42, 58, 84, 107, 121, 134, 153, 232, 234, 250, 264, 287, 289, 292, 293, 328–329
AG, 107
alcohol use disorders (AUDs), 232, 233
bulimia nervosa and binge eating disorder, 267, 268
bipolar spectrum disorder (BPD), 58–63
drug use disorders, 253, 370
generalised anxiety disorder (GAD), 84
intermittent explosive disorder (IED), 184
major depressive disorder (MDD), 46, 337
oppositional defiant disorder (ODD) and conduct disorder (CD), 213, 214
panic attacks (PAs), 99, 102
panic disorder (PD), 346
posttraumatic stress disorder (PTSD), 157, 158
social anxiety disorder (SAD), 121, 124, 125
separation anxiety disorder (SEPAD), 169, 172, 173
specific phobia, 140
aggression, 182
aggressiveness, 183
agoraphobia (AG), 106. See also Specific phobia
age at selected percentiles, 110, 349
age-of-onset, 107
comorbidity, 113–117
DSM-IV AG, 117
epidemiology of, 106
as independent disorder, 118
method, 106–107
persistence, 107
prevalence, 107, 118
of agoraphobia in World Mental Health surveys, 108–109
without panic disorder in World Mental Health surveys, 347, 348
role impairment, 107–113
severity of role impairment, 111–112, 350
socio-demographic correlates, 113, 114–115
treatment, 113
agoraphobic fears, 106
alcohol abuse (ALA), 186, 223, 224
average lifetime prevalence rate, 232
onset, 205
alcohol dependence (ALD), 223, 224
average lifetime prevalence rate, 232
alcohol-use disorders (AUDs), 223, 244. See also Oppositional defiant disorder (ODD); Posttraumatic stress disorder (PTSD)
AOO, 232, 234
average lifetime prevalence of, 239
categories, 223
comorbidity, 234, 237
concept and diagnostic criteria for, 240
differences in, 239
methods, 225
persistence, 232–234
prevalence, 224, 225–231
role impairment, 234, 237
socio-demographic correlates, 234, 235–236
treatment, 234–239
ALD. See Alcohol dependence (ALD)
American Psychiatric Association (APA), 209
amphetamines, 243
AN. See Anorexia nervosa (AN)
analysis weights, construction of, 16–18
anger, 182
attacks, 183, 184, 186
animal fear, 136
Annual Reports Questionnaire (ARQ), 243
anorexia nervosa (AN), 2, 263
anxiety, 120
Agoraphobia (AG), 107
as independent disorder, 118
method, 106–107
persistence, 107
prevalence, 107, 118
of agoraphobia in World Mental Health surveys, 108–109
without panic disorder in World Mental Health surveys, 347, 348
role impairment, 107–113
severity of role impairment, 111–112, 350
socio-demographic correlates, 113, 114–115
treatment, 113
agoraphobic fears, 106
alcohol abuse (ALA), 186, 223, 224
average lifetime prevalence rate, 232
onset, 205
alcohol dependence (ALD), 223, 224
average lifetime prevalence rate, 232
alcohol-use disorders (AUDs), 223, 244. See also Oppositional defiant disorder (ODD); Posttraumatic stress disorder (PTSD)
AOO, 232, 234
average lifetime prevalence of, 239
categories, 223
comorbidity, 234, 237
concept and diagnostic criteria for, 240
differences in, 239
methods, 225
persistence, 232–234
prevalence, 224, 225–231
role impairment, 234, 237
socio-demographic correlates, 234, 235–236
treatment, 234–239
ALD. See Alcohol dependence (ALD)
American Psychiatric Association (APA), 209
amphetamines, 243
AN. See Anorexia nervosa (AN)
analysis weights, construction of, 16–18
anger, 182
attacks, 183, 184, 186
animal fear, 136
Annual Reports Questionnaire (ARQ), 243
anorexia nervosa (AN), 2, 263
anxiety, 120
disorders, 93, 324
AOG. See Age-at-onset (AOG)
APA. See American Psychiatric Association (APA)
area probability methods, 14
ARQ. See Annual Reports Questionnaire (ARQ)
Attention-Deficit Hyperactivity Disorder (ADHD), 195, 297. See also Alcohol-use disorders (AUDs); Posttraumatic stress disorder (PTSD)
ADHD Clinical Diagnostic Scale (ACDS), 196
adult, 203
impairments in, 205–206
multiple imputation strategy to arrive at, 195–196
prevalence, 201–203, 206
role impairment, 195
childhood, 203
comorbidity, 199, 201
diagnostic assessment, 195
disability, 199, 201
multiple imputation strategy, 195–196
prevalence in adulthood, 196, 197, 201
socio-demographic correlates of, 196, 198–199
threshold and subthreshold
childhood, 204
AUDs. See Alcohol-use disorders (AUDs)
Austrian National Survey of Mental Health and Well-being (NSMHWB), 106
Balanced Repeated Replication method, 18
BED. See Binge-eating disorder (BED)
bi-directional associations between PEs and mental disorders, 293–294
bifactor models, 300
binge-eating disorder (BED), 103, 263. See also Drug-use disorders (DUD); Mental disorders
AOO and persistence, 264, 267, 268
associations with BMI, 264, 266, 269, 270
method, 263–264
prevalence, 264, 265, 266
socio-demographic correlates, 266–267, 271–272, 273–274
treatment, 268, 275–276, 277–280
bipolar disorder (BPD), 57, 300. See also Generalized anxiety disorder (GAD); Major depressive disorder (MDD); Panic Disorder (PD)
age at selected percentiles on standardized age-of-onset, 61–62
comorbidity, 67
comorbidity, 199, 201
multiple imputation strategy, 195–196
prevalence in adulthood, 196, 197, 201
socio-demographic correlates of, 196, 198–199
threshold and subthreshold
childhood, 204
AUDs. See Alcohol-use disorders (AUDs)
Australian National Survey of Mental Health and Well-being (NSMHWB), 106
Balanced Repeated Replication method, 18
BED. See Binge-eating disorder (BED)
bi-directional associations between PEs and mental disorders, 293–294
bifactor models, 300
binge-eating disorder (BED), 103, 263. See also Drug-use disorders (DUD); Mental disorders
AOO and persistence, 264, 267, 268
associations with BMI, 264, 266, 269, 270
method, 263–264
prevalence, 264, 265, 266
socio-demographic correlates, 266–267, 271–272, 273–274
treatment, 268, 275–276, 277–280
bipolar disorder (BPD), 57, 300. See also Generalized anxiety disorder (GAD); Major depressive disorder (MDD); Panic Disorder (PD)
age at selected percentiles on standardized age-of-onset, 61–62
AOO, 58–63
BP-I disorder, 57
BP-II disorder, 57
comorbidity, 67
comparative frequency-intensity of manic, hypomanic, and depressive episodes, 66–67
complete model with, 306, 308–310
method, 58
placement, 304
prevalence, 58
prevalence of DSM-IV bipolar spectrum disorder, 59–60
rapid cycling, 66
role impairment, 67–69
bipolar disorder (BPD) (cont.)
severity of role impairment, 70–71
socio-demographic correlates, 63–66
treatment, 69–74
12-month bipolar spectrum disorder, 72–73
bipolar mood disorders, 82
bipolar spectrum disorder, 57, 58
bivariate associations between socio-demographics correlates and DSM-IV, 64–65
comorbidity, 68
30-day prevalence, 63
bivariate associations between socio-demographic correlates and DSM-IV oppositional defiant disorder, 375, 376, 377
and DSM-IV posttraumatic stress disorder, 362–363
and DSM-IV social anxiety disorder, 352–353, 354–355
and posttraumatic stress disorder, 364–365, 366–367
time-lagged, 67
BMI. See Body-Mass Index (BMI)
BN. See Bulimia nervosa (BN)
body mass index (BMI), 264
BPD. See Bipolar disorder (BPD)
bulimia nervosa (BN), 263, 328
AOO and persistence, 264, 267, 268
associations with BMI, 264
comorbidity, 267–268, 275, 276
impairment in role attainment and role functioning, 264, 266, 269, 270
method, 263–264
prevalence, 264, 265, 266
socio-demographic correlates, 266–267, 271–272, 273–274
treatment, 268, 275–276, 277–280
Burden of Mental Disorders, The, 69
CAM sector. See Complementary-alternative medical sector (CAM sector)
cannabis, 243, 245
CAPI. See Computer-assisted personal interview (CAPI)
case-control sampling, 34
CCP. See Clinical contact person (CCP)
CD. See Conduct disorder (CD)
centralized screening procedures, 29
CFAs. See Confirmatory factor analyses (CFAs)
CFI. See Comparative Fit Index (CFI)
childhood
ADHD prevalence and persistence into adulthood, 196, 197, 201, 203
childhood-onset disorders, 219
CI. See Confidence interval (CI)
CIDI. See Composite International Diagnostic Interview (CIDI)
clinical characteristics, likelihood of receiving treatment across service sectors by, 315, 317
clinical contact person (CCP), 30
cocaine, 243, 245
combining strategies, 24–25
common disorders, complete model with, 306, 308–310
common mental disorders, 301–304
community surveys methodology, 4
of ADHD with other mental disorders, 199, 201
among disorders, 34–35
analyses, 80
AUDs, 234, 237
bipolar spectrum disorder, 68
of DSM-IV and DSM-5 generalized anxiety disorder, 83
GAD, 82
of major depressive disorder, 45, 46
with mental disorders, 267
of binge-eating disorder with hierarchy with DSM-IV disorders, 275
of bulimia nervosa with DSM-IV disorders, 275
in ODD and CD, 215–218
with other DSM-IV disorders, 186–187, 190
of PTSD, 158–162
SAD, 128, 131
specific phobia, 140, 144–145
Comparative Fit Index (CFI), 301
comparative frequency-intensity of manic, hypomanic, and depressive episodes, 66–67
complementary-alternative medical (CAM) sector, 27, 239, 257, 315
complex designs, 18, 19
complex sample designs for WMH surveys, 13–14
Composite International Diagnostic Interview (CIDI), 4, 9, 21, 25, 41, 80, 106, 153, 168, 183, 287
CIDI Version 3.0, 27, 29, 80, 121, 195, 225
module for SEPAD, 169
symptom, 263–264
translations, 28
canadian English version of the CIDI, 28
computer-assisted personal interview (CAPI), 28
condition-specific SDS scales, 27
conduct disorders (CD), 209, 297
age-of-onset for ODD and, 213, 214
during childhood, 209
comorbidity, 215–218
cross-national lifetime prevalence estimates, 218
epidemiological studies, 210
impairment and treatment, 218
methods, 210
persistence, 214–215
prevalence, 211–212
prevalence, course, and correlates of, 209–210
socio-demographic correlates, 215–217
use of multiple informants, 219
confidence interval (CI), 18, 33, 63
configural invariance, 299, 301, 302, 311
confirmatory factor analyses (CFAs), 300
contemporary psychiatric nosology and epidemiology, criticisms of, 5–7
contingent feedback approach, 23
contingent reinforcement, 23
Cox proportional hazards analysis approach, 33
cross-disorder perspective, 324
cross-national analyses, 301
datasets, 300–301
mental disorders, 300
bivariate associations of lifetime mental disorders, 298
common mental disorders, 301–304
community surveys methodology, 4
complete model with common disorders, 306, 308, 309, 310
criticisms of contemporary psychiatric nosology and epidemiology, 5–7
differences, 33
diagnosis of mental disorders, 3
global collaborative research networks, 5
time prevalence of CD, 211
operationalization of mental disorders, 3–4
pattern, 328
perspective, 324
placement bipolar disorders, 304
eating disorders, 305
IED, 305–306
psychotic experiences, 306, 307, 308
prevalence, 287–289
scoring system, 26
structure of mental disorders, 29
cultural adaptation of survey methods, 29
cumulative AOO distributions of PEAs, 293
cumulative lifetime probability curves, 31, 32
cumulative lifetime probability distributions, estimating, 31
DALYs. See Disability-adjusted Life Years (DALYs)
datasets, 300–301
defensive aggression, 182
delusional experiences (DEs), 286
depression, 120, 182
depressive disorder, 338–339, 340–341
DEs. See Delusional experiences (DEs)
design effect, 18, 19, 20
Diagnostic and Statistical Manual of Mental Disorders (DSM), 3, 120
DSM-defined specific phobia, 134
DSM-III diagnosis, 120
DSM-IV and DSM-5, 3
DSMIV-TR, 223
diagnostic assessment, 195
diagnostic criteria, 3, 4, 6
for CD, 210
for ODD, 210
Diagnostic Interview Schedule (DIS), 4, 195, 224

© in this web service Cambridge University Press  www.cambridge.org
disability-adjusted life years (DALYs), 223
discrete-time survival analysis, 33
disorder
disorder-specific analyses, 34–35
interaction between disorder
severity and socio-demographic
characteristics, 319
persistence, 107, 136, 232–234, 250
double sampling' technique, 13
drug abuse (DRA), 243
drug dependence (DRD), 243
drug-use disorders (DUD), 225, 243. See also Binge-eating disorder (BED);
Mental disorders
AOO, 250, 253
comorbidity, 254, 257
demographics, 254, 255–256
methods, 244–245
prevalence, 250
12-month prevalences of DRA and
DRD, 250
role impairment, 250, 254
treatment, 257–258
DSM. See Diagnostic and Statistical
Manual of Mental Disorders (DSM)
DSM-IV. See Fourth Edition of the
Diagnostic and Statistical Manual (DSM-IV)
DUD. See Drug-use disorders (DUD)
dysfunctional exaggeration, 167
Western Mediterranean region, 239
eating disorders, 263, 267, 305, 324
IED and, 306
incidence, 281
lifetime treatment of, 275
placement, 305
ECA. See Epidemiological Catchment Area
Study (ECA)
educational status, 25–26
EFA. See Exploratory factor analyses (EFA)
Epidemiological Area Catchment Study
(ECA), 49, 94
episode persistence, 107
episodic memory, 23
European Study of the Epidemiology of
Mental Disorders (ESEMED), 42
exploratory factor analyses (EFA), 301
externalizing
domains, 297
factor, 299
Feighner criteria, 3, 4
FME. See Frequent mood episodes (FME)
four-stage designs, 14
Fourth Edition of the Diagnostic and
Statistical Manual (DSM-IV), 1, 9, 106, 153, 168
AG, 117
age at selected percentiles on
standardized age-of-onset
distributions of PD, 346
bivariate associations between socio-
demographic correlates and SAD,
352–355, 356–357
BN criteria, 263–264
comorbidity, 177, 178
comorbidity of specific phobia with
other disorders, 360
'free-floating' anxiety, 79
frequent mood episodes (FME), 66
GAD. See Generalized anxiety disorder
(GAD)
GBD study. See Global Burden of Disease
study (GBD study)
general interviewing training (GIT), 29–30
general medical sector, 27
generalized anxiety disorder (GAD), 4, 27,
79, 324. See also Bipolar disorder
(BPD); Major depressive disorder
(MDD); Panic Disorder (PD)
bivariate associations of socio-
demographic variables, 87–88
comorbidity, 82
course and correlates, 84–86
DSM-IV conceptualization of, 79
help-seeking samples, 80
methods, 80
prevalence, 80–82
role impairment, 82
treatment, 82, 85, 84, 90
GIT. See General interviewing
training (GIT)
Global Burden of Disease study (GBD
study), 5, 243, 326
global collaborative research networks, 5
global mental health, 5
hallucinatory experiences (HEs), 286
Harvard Medical School (HMS), 16
HD. See Hyperactivity-impulsivity (HD)
help-seeking samples, 80
heroin, 243
HEs. See Hallucinatory experiences (HEs)
 hierarchical coding scheme, 25
high-income countries, 356, 366, 377
higher-order model with bipolar
disorder, 304
HMS. See Harvard Medical School (HMS)
human services sector, 27
hyperactivity-impulsivity (HD), 195
hypomanic episodes, comparative
frequency-intensity of, 66–67
ICD. See International Statistical
Classification of Diseases (ICD)
ICPE. See International Consortium in
Psychiatric Epidemiology (ICPE)
IED. See Intermittent explosive
disorder (IED)
ipimpairment
role, 67–69, 107–113, 184, 250, 254
attainment and role functioning,
264, 266
severity of role impairment
associated with 12-month binge-eating
disorder, 269
associated with 12-month bulimia
nervosa, 270
in specific phobia, 135, 141,
146–147, 148
and treatment of ODD and CD, 218
impulsive aggression, 182
Institute for Social Research (ISR), 9–10
inter-quartile range (IQR), 58, 107, 184
intermittent explosive disorder (IED),
182, 187, 324. See also Alcohol-use
disorders (AUDs); Attention-
Deficit Hyperactivity Disorder (ADHD); Posttraumatic stress
disorder (PTSD)
age-of-onset, 184
associations of traumatic events with
onset of IED, 187, 191
comorbidity, 186–187, 190
in DSM-IV, 182
lifetime prevalence, 187, 190
median age-of-onset, 191
method, 183–184
placement, 305–306
prevalence, 184, 185, 192
role impairment, 184, 186
socio-demographic correlates,
186, 188–189
treatment, 187
type of anger attacks in past 12 months,
184, 186
internalizing disorders, 299
internalizing domains, 297
International Consortium in Psychiatric
Epidemiology (ICPE), 5
International Statistical Classification of
Diseases (ICD), 3, 4, 118, 120
ICD-10, 9
interviewer training, 29
interviewer hiring and training, 29–30
and quality control monitoring, 28, 30
IQR. See Inter-quartile range (IQR)
ISR. See Institute for Social Research (ISR)
JackKnife Repeated Replication method
(JRR method), 18
life-time
comorbidity, 177, 178
prevalence, 30–31, 107
IED, 187, 190
of PTSD, 154
likelihood of receiving treatment
across
by clinical characteristics, 315, 317
by socio-demographic characteristics,
315, 318–319
logistic link function, 34
logistic regression analysis, 17
low and middle-income countries, 5
low/lower-middle-income countries, 352–353, 362–363, 375
lower bound estimates, 31
major depression, 26, 27, 41, 55, 58, 282, 330
major depressive disorder (MDD), 41, 79, 324. See also Bipolar disorder (BPD); Generalized anxiety disorder (GAD); Panic Disorder (PD)
age-of-onset distributions of DSM-IV MDD, 337
AOO and projected lifetime risk of, 46 bivariate associations between socio-demographics, 52–53 comorbidity of major depressive disorder, 45, 46 method, 42 prevalence and persistence, 42–46 role impairment, 46–49 socio-demographic correlates, 49–54 socio-economic factors, 41 treatment, 49
12-month major depressive disorder, 50–51
panic attacks (PAs), 93 comorbidity of single and recurrent, 100–101 prevalence and age-of-onset of types of, 102 in WMHS 30-day prevalence of, 344–345 12-month prevalence of, 342–343 panic disorder (PD), 93, 106. See also Bipolar disorder (BPD); Generalized anxiety disorder (GAD); Major depressive disorder (MDD) age-at-onset distributions on standardized age-of-onset distributions of agoraphobia without, 349 of DSM-IV, 346 comorbidity and correlates, 95, 99 epidemiology, 93–94, 106 essential feature, 93 lifetime prevalence of panic attack and DSM-IV, 96–97 method, 94–95 number and type of PAs, 99 prevalence, 95 role impairment and treatment, 95 severity of role impairment, 98 associated with 12-month agoraphobia without PD, 350–351 in WMHS prevalence of agoraphobia without, 347, 348 30-day prevalence, 344–345 12-month prevalence, 342–343 paper and pencil interview (PAPI), 28 PAPI. See Paper and pencil interview (PAPI) PAs. See Panic attacks (PAs)
Bipolar disorder (BPD); Generalized anxiety disorder (GAD); Drug-use disorders (DUD); Generalized anxiety disorder (GAD) ability to answer accurately, 23–24 bi-directional association between PEs and, 293–294 combining strategies, 24–25 comorbidity of ADHD with, 199, 201 between disorders, 330–331 cross-national epidemiology, 3–7 impact, 329 variation across countries, 329–330 variation across disorders, 329 life course, 328–329 motivation, 22–23 operationalization, 3–4 persistence, 328 policy implications, 331–332 prevalence, 324 variation across countries, 326–328 variation across disorders, 324–326 question comprehension, 21–22 study limitations, 331 task comprehension, 22 mental health specialist sector, 27 treatment gap, 314 MG-CFA. See Multigroup-CFA (MG-CFA)
MI. See Multiple imputation (MI) mood disorders, 82 morbid risk, 31, 32 motivation, 22–23 multigroup-CFA (MG-CFA), 301 multiple imputation (MI), 196 to arriving at adult ADHD prevalence estimates, 195–196 multivariate significance tests, 33 National Comorbidity Study, 94, 134 National Comorbidity Study Replication (NCS-R), 94, 153 National Comorbidity Survey, 41 National Epidemiological Survey on Alcohol and Related Conditions (NESARC), 94, 134 National Institutes of Health in United States, 5 NCS. See National Comorbidity Study (NCS)
NCS-R. See National Comorbidity Study Replication (NCS-R) negative predictive value (NPV), 57 NESARC. See National Epidemiological Survey on Alcohol and Related Conditions (NESARC)
Netherlands Mental Health Survey and Incidence Initiative (NEMESIS), 134 nonresponse adjustment weight, 16 surveys, 15–16 NPV. See Negative predictive value (NPV) NSMHWB. See Australian National Survey of Mental Health and Well-being (NSMHWB)
obcessive compulsive disorder (OCDD), 2, 297
ODD. See Oppositional defiant disorder (ODD)
odds-ratios (ORs), 33, 34, 63, 191, 199 older mental-health studies, 299–300 oppositional defiant disorder (ODD), 209, 297, 376. See also Alcohol-use disorders (AUDs); Attention-Deficit Hyperactivity Disorder (ADHD)
age-of-onset for, 213, 214 during childhood, 209 comorbidity, 215–218 cross-national lifetime prevalence estimates, 218 epidemiological studies, 210 impairment and treatment, 218 methods, 210 persistence, 214–215 prevalence, 211–212 prevalence, course, and correlates of, 209–210 socio-demographic correlates, 215–217 symptoms, 209 use of multiple informants, 219 ORs. See Odds-ratios (ORs) outcome variables, prevalence of, 30–31 panic attacks (PAs), 93 comorbidity of single and recurrent, 100–101 prevalence and age-of-onset of types of, 102 in WMHS 30-day prevalence of, 344–345 12-month prevalence of, 342–343 panic disorder (PD), 93, 106. See also Bipolar disorder (BPD); Generalized anxiety disorder (GAD); Major depressive disorder (MDD)
age-at-onset distributions on standardized age-of-onset distributions of agoraphobia without, 349 of DSM-IV, 346 comorbidity and correlates, 95, 99 epidemiology, 93–94, 106 essential feature, 93 lifetime prevalence of panic attack and DSM-IV, 96–97 method, 94–95 number and type of PAs, 99 prevalence, 95 role impairment and treatment, 95 severity of role impairment, 98 associated with 12-month agoraphobia without PD, 350–351 in WMHS prevalence of agoraphobia without, 347, 348 30-day prevalence, 344–345 12-month prevalence, 342–343 paper and pencil interview (PAPI), 28 PAPI. See Paper and pencil interview (PAPI) PAs. See Panic attacks (PAs)
PD. See Panic Disorder (PD)
People’s Republic of China (PRC), 121, 168 persistence, 264 of AG, 107 AUDs, 232 of ODD and CD, 214–215 person-level analysis, 16 person-year models, 33–34 PEs. See Psychotic experiences (PEs) phobia, 120 phobic stimulus, 134 population registry approach, 13 positive predictive value (PPV), 57 poststratification factor, 17 weighting step, 16 posttraumatic stress disorder (PTSD), 26, 153, 315, 324. See also Attention-Deficit Hyperactivity Disorder (ADHD); Intermittent explosive disorder (IED); Separation anxiety disorder (SEPAD); Social anxiety disorder (SAD)

© in this web service Cambridge University Press www.cambridge.org
statistical analysis methods (cont.)
  prevalence of outcome variables, 30–31
  socio-demographic correlates of lifetime disorders, 32–34
  treatment of 12-month disorders, 35
Structured Clinical Interview for DSM-IV (SCID), 80, 136, 169
study-specific training, 30
substance-use disorders (SUDS), 225
subthreshold
BPD, 57
childhood ADHD, 204
SUDS. See Substance-use disorders (SUDS)
survey
cost structures, 13
population, 10
response rates, 14
Survey Research Center (SRC), 10
survivor bias, 54
symptom persistence, 136, 140
systematic monitoring, 30
target populations, 10–13
task comprehension, 22
taylor series linearization method, 18
TE. See Traumatic event (TE)
thirty-day prevalence, 31
decomposing socio-demographic correlating, 34
of PTSD, 157
three-stage designs, 14
threshold childhood ADHD, 204
time-lagged associations between PEs and mental disorders, 294–295
time-since-onset (TSO), 25, 63
'train-the-trainer' session, 29
translation, 27–28
traumatic event (TE), 153, 154
associations with onset of IED, 187, 191
categories, 154
prevalence, 154
treatment/service use, 27, 49
methods, 314–315
type, 315, 316
interaction between disorder severity and socio-demographic characteristics, 319
likelihood of receiving treatment across service sectors, 315, 317
socio-demographic characteristics, 315, 318–319
TSO. See Time-since-onset (TSO)
12-month/lifetime ratio, 289
12-month ADHD
adult ADHD treatment, 206
disability in, 199, 201
treatment of, 201–203
12-month prevalence, 31, 34
of CD, 211
of PTSD, 154
12-month treatment, 27, 35, 69, 203, 275
two-part interview design, 14–15
two-stage design, 13
unbiasedness, 17
unipolar mood disorders, 82
United Nations Office on Drugs and Crime (UNODC), 243
United States (US), 41, 94, 153
universal health coverage, 332
UNODC. See United Nations Office on Drugs and Crime (UNODC)
unspecified bipolar disorder, 57
upper-middle income countries, 354, 364, 376
WDR. See World Drug Report (WDR)
Weighted Least Squares estimation for categorical data (WLSMV), 301
weighting, 16
construction of analysis weights, 16–18
WMH poststratiﬁcation, 17
Westernized, educated, industrialized, rich, and democratic countries (WEIRD countries), 120
WFS programme. See World Fertility Survey programme (WFS programme)
WHO. See World Health Organization (WHO)
WHO Disability Assessment Schedule (WHO-DAS), 199
WLSMV. See Weighted Least Squares estimation for categorical data (WLSMV)
WMH. See World Mental Health (WMH)
World Drug Report (WDR), 243
World Fertility Survey programme (WFS programme), 9
World Health Organization (WHO), 1, 4, 9, 41, 168, 209, 223, 287, 314, 332
World Mental Health (WMH), 1, 3, 5, 9, 41, 57, 80, 135, 168, 182, 223, 243–244, 263, 286, 314, 324
collaborators, 28
data Collection Coordination Centre, 29
data on epidemiology of SAD, 132
interviewer training and quality control monitoring, 28–30
measures
mental disorders, 19–25
pretesting, 28
role impairment, 26–27
socio-demographics, 25–26
translation, 27–28
treatment/service use, 27
sampling, 9
characteristics by World Bank Income categories, 11–12
complex sample designs for WMH surveys, 13–14
error and inference from WMH survey data, 18–19
frames, 13
nonresponse surveys, 15–16
target populations, 10–13
two-part interview design, 14–15
weighting, 16–18
statistical analysis methods, 30–35
Surveys Initiative, 9
YDLs. See Years lived with disability (YDLs)